Skip to content
To the full analysis

Valerio Therapeutics stock: balance sheet and debt

ALVIO.PA
$0.50Closing price of 12 Nov 2026MEQIRI Score 40 out of 100

Valerio Therapeutics has a debt to equity ratio of 3.67.

Debt / Equity
3.67
Interest coverage
−15.5x
Current ratio
0.76
Cash & equivalents
$1.17M
Total assets
$16.88M
Equity ratio
13.6%
Goodwill
$9.06M
Net debt
$7.26M

Total assets and equity ratio

How large the balance sheet of Valerio Therapeutics S.A. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$25.17M$129.29Knot split out83.5%−$19.47M
2007$70.41M$132.45Knot split out73.2%−$62.32M
2008$46.95M$98.82Knot split out64.2%−$35.1M
2009$23.64M$143.94Knot split out59.8%−$16.22M
2010$29.18M$129.52Knot split out71.6%−$23.15M
2011$37.76M$29.52Knot split out67.2%−$31.58M
2012$24.51M$36.03Knot split out53.1%−$16.01M
2013$19.66M$25.25Knot split out41.9%−$12.45M
2014$168.43M$97.44M$22.23M80.2%−$61.61M
2015$143.21M$95.7M$22.23M79.5%−$37.37M
2016$138.62M$96.64M$22.23M75.2%−$32.29M
2017$86.51M$52.67M$22.23M63.9%−$15.68M
2018$70.09M$42.74M$22.23M71.8%−$4.67M
2019$41.7M$25.88M$20.01M45.7%$3.18M
2020$51.53M$22.75M$20.01M62.4%−$9.16M
2021$58.8M$22.75M$20.01M62.1%−$8.81M
2022$47.74M$22.97M$20.23M51.7%−$4.98M
2023$39.09M$22.75M$20.01M42.0%$2.42M
2024$19.87M$13.26M$13.26M−46.1%$13.58M
2025$16.88M$9.06M$9.06M13.6%$7.26M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$19.53M$21.03M$62.08K0
2007$62.34M$51.52M$23.82K0
2008$35.12M$30.16M$12.95K0
2009$16.3M$14.14M$82.58K0.01
2010$23.21M$20.89M$63.23K0
2011$31.76M$25.38M$188.39K0.01
2012$16.07M$13.01M$63.09K0
2013$12.55M$8.24M$101.04K0.01
2014$63.41M$135.16M$1.81M0.01
2015$37.45M$113.91M$76.46K0
2016$32.4M$104.26M$117.46K0
2017$15.82M$55.27M$144.05K0
2018$12.47M$50.31M$7.8M0.16
2019$6.33M$19.06M$9.51M0.5
2020$16.09M$32.17M$6.93M0.22
2021$19.82M$36.5M$11.01M0.3
2022$16.16M$24.68M$11.18M0.45
2023$7.56M$16.41M$9.97M0.61
2024$1.31M−$9.9M$14.89M−1.63
2025$1.17M$2.3M$8.43M3.67

Data status and sources

Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Currency
Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2024)
  • Valuation signal Overvalued since 10 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy